Home › Vaso-Occlusive Crises › Georgia
Vaso-Occlusive Crises clinical trials in Georgia
4 studies for Vaso-Occlusive Crises are looking for participants at sites in Georgia.
Cities in Georgia
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Augusta University Georgia, Augusta
- WCG Sonar Clinical Research, Riverdale
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Sep 28, 2026 · NCT06439082Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Arthur M. Blank Hospital-Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Aug 14, 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Arthur M. Blank Hospital- Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07224360Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Augusta University Georgia, Augusta
RecruitingPhase 4
6 Months – 100 Years · All sexes · Updated Jun 8, 2026 · NCT04657822From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.